Increase of human platelet serotonin uptake by atypical histamine receptors.
Histamine and the guanosine 3',5'-cyclic monophosphate (cGMP)-inducing agent sodium nitroprusside both increased serotonin (5-HT) uptake and cGMP levels in isolated human platelets in vitro. Histaminergic stimulation was observed at concentrations ranging from 10 nM to 0.25 microM [mean effective concentration (EC50) = 0.1 microM histamine]. The inhibition produced by the H2-receptor antagonists tiotidine, metiamide, and cimetidine was 10-10(5) times more potent on histamine receptors regulating 5-HT uptake and cGMP generation in human platelets than on the histaminergic receptors H1, HIC, H2, and H3 in other tissues. The in vitro histamine-induced 5-HT uptake was prevented by preincubation of isolated human platelets in the presence of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine or the cGMP-lowering agent LY-83583. Histamine was ineffective in stimulating cAMP generation in human platelets and did not interact with effector sites known to downregulate 5-HT uptake, including imipramine, gamma-aminobutyric acid A, peripheral type benzodiazepine-binding sites, and V1a vasopressin receptors inducing human platelet shape change and aggregation. These atypical human platelet histaminergic receptors differ from the previously classified histamine receptors by their apparent high affinity to histamine H2-receptor antagonists and their apparent link with the soluble, nitric oxide-dependent guanylate cyclase. These findings suggest that human platelets express a new subtype H2h of histamine receptors.
Launay
J M
JM
Formation de Recherche Associée Claude Bernard, Neurochimie des Communications Cellulaires, Hôpital Saint-Louis, Paris, France.
Bondoux
D
D
Oset-Gasque
M J
MJ
Emami
S
S
Mutel
V
V
Haimart
M
M
Gespach
C
C
D000328:Adult; D000634:Aminoquinolines / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002927:Cimetidine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood; D017259:Dimaprit / Q000494:pharmacology; D015738:Famotidine / Q000494:pharmacology; D005260:Female; D006633:Histamine Antagonists / Q000494:pharmacology*; D006639:Histidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D017446:Impromidine / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008785:Metiamide / Q000494:pharmacology; D008875:Middle Aged; D008954:Models, Biological; D010974:Platelet Aggregation / Q000187:drug effects; D011968:Receptors, Histamine / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000097:blood*
D000634:Aminoquinolines; D006633:Histamine Antagonists; D011968:Receptors, Histamine; D012701:Serotonin; D008785:Metiamide; D006639:Histidine; D015738:Famotidine; D002927:Cimetidine; C041715:6-anilino-5,8-quinolinedione; D017446:Impromidine; D000242:Cyclic AMP; C023990:tiotidine; D007099:Imipramine; D017259:Dimaprit